New developments in anticoagulants: Past, present and future

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Thrombosis poses a significant global health risk, necessitating effective anticoagulant therapies.
• Traditional anticoagulants include unfractionated heparin (UFH) and vitamin K antagonists (VKAs).
• Recent advancements have introduced safer and more convenient anticoagulant options.

Purpose of the Study:

• To highlight recent advances in anticoagulant therapies.
• To discuss the role of specific reversal agents for novel oral anticoagulants (NOACs).
• To review ongoing clinical trials and emerging anticoagulant targets.

Main Methods:

• Review of current literature on anticoagulant drug development and clinical use.
• Analysis of the advantages of low-molecular-weight heparin, fondaparinux, and bivalirudin over UFH.
• Examination of the efficacy, safety, and convenience of NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) compared to VKAs.

Main Results:

• Low-molecular-weight heparin and fondaparinux have largely replaced UFH for venous thromboembolism prevention and treatment.
• Bivalirudin is increasingly used in percutaneous interventions.
• NOACs demonstrate comparable efficacy to VKAs with improved safety and convenience, leading to their wider adoption.

Conclusions:

• The landscape of anticoagulant therapy has evolved, offering improved options for patients.
• Development of specific reversal agents for NOACs is expected to further enhance their safety profile.
• Emerging anticoagulants targeting Factor XII and XI represent future therapeutic avenues.